Navigation Links
Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory
Date:5/15/2009

SANTA MONICA, Calif., May 15 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Company founder and CEO Matthew Schissler, in a FirstCall In audio interview with analyst Francis Gaskins, explains the thought process behind the Company owning its own stem cell laboratory.

The interview and associated web links are available at http://www.investorcalendar.com/IC/ClientPage.asp?ID=145109.

An analyst report compiled by Mr. Gaskins, which details Cord Blood America's effort to become cash flow positive this year, is available at http://gaskinsco.com/linkto-cbai.shtml

"The laboratory will allow Cord Blood America to store the cells of its clients, potentially saving a tremendous amount of money in the long run," Mr. Schissler said. "Also, it allows CBAI to sell storage services to other cryogenic tissue storage companies, and allows Cord Blood America to diversify its stem cell storage base, opening up the market greatly. This vertical integration will create a competitive advantage for the Company."

For further updated information, please follow Cord Blood America at http://twitter.com/StemCellBanking, http://twitter.com/cbai, and http://stem-cell-banking.blogspot.com/ .

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

        CONTACT:
        Paul Knopick
        E & E Communications
        949/707-5365
        pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
2. Viral Infection Might Trigger High Blood Pressure
3. Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory
4. New research confirms milestone study on blood pressure meds
5. AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
6. Study finds iron levels not predictive of survival for form of blood cancer
7. Genes Yield Clues to High Blood Pressure
8. Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
9. Too-Low Blood Pressure Can Also Bring Danger
10. All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke
11. Phone Monitoring May Help Lower Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Consultative health ... and GM Jim Callandrillo and Duane Reed, VP of business development of AJMC ... Intelligence and Research Group (PBIRG) General Meeting from May 15-17 at the ...
(Date:5/2/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased to announce its ... the Pharma Landscape .” CMS recently proposed a test of alternate payment models for ... preserving care provided to beneficiaries. The webinar will review the details of this model, ...
(Date:5/2/2016)... ... May 02, 2016 , ... For many artists, the act ... Walter has developed it into a science. , Using the new, highly precise ... differentiated shades that add depth and meaning to his works. What’s more, it has ...
(Date:5/2/2016)... ... 2016 , ... The debilitating disease of arthritis can bring patients a hefty ... must deal with prescription costs to treat arthritis over the course of a lifetime. ... the pharmacy on many common prescriptions. , Arthritis , Although arthritis is a very ...
(Date:5/2/2016)... ... May 02, 2016 , ... Summit BHC ... the opening of Twin Lakes Recovery Center. Located east of Atlanta in ... state. The residential facility is set on 34 acres of beautiful, secluded ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
Breaking Medicine Technology: